American Society of Hematology (ASH), 2021


  1. Effects of prior exposure to Tec kinase (BTK/ITK) inhibitors on KTE-X19 products
  2. Profiling the peripheral blood immune cell repertoire in large-B cell lymphoma patients treated with CD19 CAR-T
  3. Prediction of Early Onset Cytokine Release Syndrome and Neurologic Events after Axicabtagene Ciloleucel in Large B-Cell Lymphoma Based on Machine Learning Algorithms
  4. TNFR2 as a Target to Improve CD19-Directed CAR T Cell Fitness and Antitumor Activity in Large B Cell Lymphoma
  5. Chimeric Antigen Receptor T-Cell Therapy Treatment Patterns: A Retrospective Cohort Analysis of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients in the US
  6. The Comparison of KTE-X19 to Current Standards of Care: A Prespecified Synthetic Control Study Utilizing Individual Patient-Level Data from Historic Clinical Trials (SCHOLAR-3)
  7. A Comparison of Clinical Outcomes from Updated ZUMA-5 (Axicabtagene Ciloleucel) and the International SCHOLAR-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma
  8. Prophylactic Corticosteroid Use With Axicabtagene Ciloleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma: One-Year Follow-Up of ZUMA-1 Cohort 6
  9. A Phase II Trial of Anakinra for the Prevention of CAR T-Cell Mediated Neurotoxicity
  10. Long-Term (4 Year and 5 Year) Overall Survival in ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel in Patients with Refractory Large B-Cell Lymphoma
  11. Long-Term Follow-Up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
  12. Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel as First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma
  13. Real-World Outcomes of Axicabtagene Ciloleucel for the Treatment of Large B-Cell Lymphoma: Impact of Age and Specific Organ Dysfunction
  14. Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7)
  15. Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel Versus Standard-Of-Care Therapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma